nodes	percent_of_prediction	percent_of_DWPC	metapath
Bumetanide—CA7—colon cancer	0.558	0.879	CbGaD
Bumetanide—PTGS2—colon cancer	0.0767	0.121	CbGaD
Bumetanide—SLC22A7—Fluorouracil—colon cancer	0.0643	0.324	CbGbCtD
Bumetanide—SLC22A11—Methotrexate—colon cancer	0.0372	0.187	CbGbCtD
Bumetanide—SLC22A7—Methotrexate—colon cancer	0.0354	0.179	CbGbCtD
Bumetanide—SLCO1A2—Methotrexate—colon cancer	0.0248	0.125	CbGbCtD
Bumetanide—SLC22A8—Methotrexate—colon cancer	0.0216	0.109	CbGbCtD
Bumetanide—SLC22A6—Methotrexate—colon cancer	0.0151	0.0759	CbGbCtD
Bumetanide—CA14—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0123	0.163	CbGpPWpGaD
Bumetanide—CA5A—Reversible hydration of carbon dioxide—CA7—colon cancer	0.012	0.159	CbGpPWpGaD
Bumetanide—CA5B—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0112	0.149	CbGpPWpGaD
Bumetanide—CA12—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0104	0.138	CbGpPWpGaD
Bumetanide—CA4—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00828	0.11	CbGpPWpGaD
Bumetanide—SLC10A1—bile—colon cancer	0.00774	0.152	CbGeAlD
Bumetanide—CA9—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00669	0.0888	CbGpPWpGaD
Bumetanide—Furosemide—CA7—colon cancer	0.00267	0.51	CrCbGaD
Bumetanide—CFTR—gall bladder—colon cancer	0.00259	0.051	CbGeAlD
Bumetanide—Ear discomfort—Capecitabine—colon cancer	0.00255	0.0727	CcSEcCtD
Bumetanide—Indapamide—CA7—colon cancer	0.00231	0.44	CrCbGaD
Bumetanide—CA9—gall bladder—colon cancer	0.00224	0.0441	CbGeAlD
Bumetanide—SLC12A4—embryo—colon cancer	0.00209	0.0412	CbGeAlD
Bumetanide—Electrolyte imbalance—Irinotecan—colon cancer	0.0015	0.0427	CcSEcCtD
Bumetanide—CFTR—ABC-family proteins mediated transport—ABCB1—colon cancer	0.00139	0.0184	CbGpPWpGaD
Bumetanide—CFTR—epithelium—colon cancer	0.00134	0.0264	CbGeAlD
Bumetanide—CFTR—renal system—colon cancer	0.00124	0.0245	CbGeAlD
Bumetanide—CA7—renal system—colon cancer	0.00122	0.0241	CbGeAlD
Bumetanide—Azotaemia—Vincristine—colon cancer	0.00121	0.0343	CcSEcCtD
Bumetanide—SLC12A2—epithelium—colon cancer	0.00118	0.0232	CbGeAlD
Bumetanide—CA5A—liver—colon cancer	0.00112	0.0221	CbGeAlD
Bumetanide—SLC12A2—renal system—colon cancer	0.00109	0.0215	CbGeAlD
Bumetanide—SLC10A1—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.00105	0.014	CbGpPWpGaD
Bumetanide—SLC10A1—renal system—colon cancer	0.00103	0.0203	CbGeAlD
Bumetanide—CFTR—digestive system—colon cancer	0.00102	0.0201	CbGeAlD
Bumetanide—Serum creatinine increased—Irinotecan—colon cancer	0.00102	0.029	CcSEcCtD
Bumetanide—CA7—digestive system—colon cancer	0.001	0.0198	CbGeAlD
Bumetanide—SLC12A1—epithelium—colon cancer	0.000986	0.0194	CbGeAlD
Bumetanide—SLC12A4—liver—colon cancer	0.000966	0.019	CbGeAlD
Bumetanide—SLC22A11—renal system—colon cancer	0.000941	0.0185	CbGeAlD
Bumetanide—Encephalopathy—Fluorouracil—colon cancer	0.000933	0.0266	CcSEcCtD
Bumetanide—SLC22A7—renal system—colon cancer	0.000919	0.0181	CbGeAlD
Bumetanide—SLC12A1—renal system—colon cancer	0.000915	0.018	CbGeAlD
Bumetanide—SLC12A2—digestive system—colon cancer	0.000895	0.0176	CbGeAlD
Bumetanide—CA9—digestive system—colon cancer	0.000881	0.0174	CbGeAlD
Bumetanide—SLC10A1—digestive system—colon cancer	0.000846	0.0167	CbGeAlD
Bumetanide—SLC12A2—bone marrow—colon cancer	0.000825	0.0163	CbGeAlD
Bumetanide—CA12—renal system—colon cancer	0.000795	0.0157	CbGeAlD
Bumetanide—SLC12A2—vagina—colon cancer	0.00079	0.0156	CbGeAlD
Bumetanide—SLC22A11—digestive system—colon cancer	0.000772	0.0152	CbGeAlD
Bumetanide—CFTR—liver—colon cancer	0.000759	0.015	CbGeAlD
Bumetanide—SLC22A7—digestive system—colon cancer	0.000754	0.0148	CbGeAlD
Bumetanide—SLC12A4—lymph node—colon cancer	0.000741	0.0146	CbGeAlD
Bumetanide—PTGS2—endothelium—colon cancer	0.000723	0.0143	CbGeAlD
Bumetanide—Hyperuricaemia—Vincristine—colon cancer	0.000693	0.0197	CcSEcCtD
Bumetanide—Serum creatinine increased—Capecitabine—colon cancer	0.000681	0.0194	CcSEcCtD
Bumetanide—PTGS2—blood vessel—colon cancer	0.000667	0.0131	CbGeAlD
Bumetanide—SLC12A2—liver—colon cancer	0.000667	0.0131	CbGeAlD
Bumetanide—Blood uric acid increased—Vincristine—colon cancer	0.000654	0.0186	CcSEcCtD
Bumetanide—Encephalopathy—Capecitabine—colon cancer	0.000652	0.0186	CcSEcCtD
Bumetanide—CA12—digestive system—colon cancer	0.000652	0.0128	CbGeAlD
Bumetanide—Musculoskeletal pain—Vincristine—colon cancer	0.00065	0.0185	CcSEcCtD
Bumetanide—SLC10A1—liver—colon cancer	0.00063	0.0124	CbGeAlD
Bumetanide—PTGS2—gall bladder—colon cancer	0.000628	0.0124	CbGeAlD
Bumetanide—CA14—liver—colon cancer	0.000623	0.0123	CbGeAlD
Bumetanide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EP300—colon cancer	0.000614	0.00815	CbGpPWpGaD
Bumetanide—Azotaemia—Methotrexate—colon cancer	0.000585	0.0167	CcSEcCtD
Bumetanide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—VEGFA—colon cancer	0.000581	0.00771	CbGpPWpGaD
Bumetanide—SLC22A11—liver—colon cancer	0.000575	0.0113	CbGeAlD
Bumetanide—SLC22A7—liver—colon cancer	0.000561	0.0111	CbGeAlD
Bumetanide—SLCO1A2—renal system—colon cancer	0.000556	0.011	CbGeAlD
Bumetanide—Polyuria—Vincristine—colon cancer	0.000531	0.0151	CcSEcCtD
Bumetanide—SLC22A8—renal system—colon cancer	0.000531	0.0105	CbGeAlD
Bumetanide—CA5B—vagina—colon cancer	0.000516	0.0102	CbGeAlD
Bumetanide—SLC12A2—lymph node—colon cancer	0.000511	0.0101	CbGeAlD
Bumetanide—CA4—renal system—colon cancer	0.000492	0.00969	CbGeAlD
Bumetanide—Encephalopathy—Methotrexate—colon cancer	0.000486	0.0138	CcSEcCtD
Bumetanide—Hyponatraemia—Vincristine—colon cancer	0.000468	0.0133	CcSEcCtD
Bumetanide—SLCO1A2—digestive system—colon cancer	0.000456	0.00899	CbGeAlD
Bumetanide—Hyponatraemia—Irinotecan—colon cancer	0.000456	0.013	CcSEcCtD
Bumetanide—Hearing impaired—Capecitabine—colon cancer	0.00044	0.0125	CcSEcCtD
Bumetanide—CA9—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000439	0.00582	CbGpPWpGaD
Bumetanide—Dehydration—Vincristine—colon cancer	0.000434	0.0124	CcSEcCtD
Bumetanide—Blood creatinine increased—Irinotecan—colon cancer	0.000425	0.0121	CcSEcCtD
Bumetanide—Dehydration—Irinotecan—colon cancer	0.000422	0.012	CcSEcCtD
Bumetanide—Hypokalaemia—Irinotecan—colon cancer	0.000413	0.0118	CcSEcCtD
Bumetanide—Cramp muscle—Irinotecan—colon cancer	0.000409	0.0116	CcSEcCtD
Bumetanide—CA4—digestive system—colon cancer	0.000404	0.00795	CbGeAlD
Bumetanide—SLC22A7—Fluoropyrimidine Activity—TYMS—colon cancer	0.000401	0.00532	CbGpPWpGaD
Bumetanide—PTGS2—embryo—colon cancer	0.000398	0.00784	CbGeAlD
Bumetanide—Pancreatitis—Irinotecan—colon cancer	0.000385	0.011	CcSEcCtD
Bumetanide—CA4—bone marrow—colon cancer	0.000372	0.00733	CbGeAlD
Bumetanide—Polyuria—Capecitabine—colon cancer	0.000346	0.00986	CcSEcCtD
Bumetanide—Sweating—Vincristine—colon cancer	0.000345	0.00981	CcSEcCtD
Bumetanide—Renal failure—Irinotecan—colon cancer	0.000344	0.0098	CcSEcCtD
Bumetanide—SLCO1A2—liver—colon cancer	0.00034	0.0067	CbGeAlD
Bumetanide—Hyperuricaemia—Methotrexate—colon cancer	0.000336	0.00957	CcSEcCtD
Bumetanide—Sweating—Irinotecan—colon cancer	0.000336	0.00956	CcSEcCtD
Bumetanide—CA5B—lymph node—colon cancer	0.000334	0.00658	CbGeAlD
Bumetanide—PTGS2—epithelium—colon cancer	0.000325	0.0064	CbGeAlD
Bumetanide—Blood uric acid increased—Methotrexate—colon cancer	0.000317	0.00904	CcSEcCtD
Bumetanide—PTGS2—smooth muscle tissue—colon cancer	0.000313	0.00616	CbGeAlD
Bumetanide—Hyponatraemia—Capecitabine—colon cancer	0.000305	0.00869	CcSEcCtD
Bumetanide—PTGS2—renal system—colon cancer	0.000301	0.00593	CbGeAlD
Bumetanide—Blood creatinine increased—Capecitabine—colon cancer	0.000285	0.00811	CcSEcCtD
Bumetanide—Dehydration—Capecitabine—colon cancer	0.000283	0.00805	CcSEcCtD
Bumetanide—Gynaecomastia—Methotrexate—colon cancer	0.000279	0.00794	CcSEcCtD
Bumetanide—Hypokalaemia—Capecitabine—colon cancer	0.000277	0.00788	CcSEcCtD
Bumetanide—CA9—HIF-1-alpha transcription factor network—ABCB1—colon cancer	0.000274	0.00363	CbGpPWpGaD
Bumetanide—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.000274	0.0078	CcSEcCtD
Bumetanide—CA9—Cellular response to hypoxia—EP300—colon cancer	0.000271	0.0036	CbGpPWpGaD
Bumetanide—PTGS2—Overview of nanoparticle effects—BAX—colon cancer	0.00027	0.00359	CbGpPWpGaD
Bumetanide—Fenoprofen—PTGS2—colon cancer	0.000264	0.0503	CrCbGaD
Bumetanide—Muscle spasms—Irinotecan—colon cancer	0.000263	0.00749	CcSEcCtD
Bumetanide—Polyuria—Methotrexate—colon cancer	0.000258	0.00734	CcSEcCtD
Bumetanide—CA9—Cellular response to hypoxia—VEGFA—colon cancer	0.000257	0.00341	CbGpPWpGaD
Bumetanide—Vertigo—Vincristine—colon cancer	0.000252	0.00719	CcSEcCtD
Bumetanide—Abdominal discomfort—Capecitabine—colon cancer	0.000252	0.00717	CcSEcCtD
Bumetanide—Leukopenia—Vincristine—colon cancer	0.000251	0.00716	CcSEcCtD
Bumetanide—CA14—Metabolism—CA7—colon cancer	0.00025	0.00332	CbGpPWpGaD
Bumetanide—PTGS2—lymphoid tissue—colon cancer	0.00025	0.00493	CbGeAlD
Bumetanide—PTGS2—digestive system—colon cancer	0.000247	0.00487	CbGeAlD
Bumetanide—Vertigo—Irinotecan—colon cancer	0.000246	0.007	CcSEcCtD
Bumetanide—Leukopenia—Irinotecan—colon cancer	0.000245	0.00697	CcSEcCtD
Bumetanide—CA5A—Metabolism—CA7—colon cancer	0.000244	0.00324	CbGpPWpGaD
Bumetanide—Hyperglycaemia—Capecitabine—colon cancer	0.000237	0.00675	CcSEcCtD
Bumetanide—Leukopenia—Fluorouracil—colon cancer	0.000234	0.00668	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000232	0.00661	CcSEcCtD
Bumetanide—CA4—lymph node—colon cancer	0.000231	0.00454	CbGeAlD
Bumetanide—Renal failure—Capecitabine—colon cancer	0.00023	0.00656	CcSEcCtD
Bumetanide—CA5B—Metabolism—CA7—colon cancer	0.000228	0.00302	CbGpPWpGaD
Bumetanide—PTGS2—bone marrow—colon cancer	0.000228	0.00449	CbGeAlD
Bumetanide—Thrombocytopenia—Vincristine—colon cancer	0.000224	0.00639	CcSEcCtD
Bumetanide—Chest pain—Fluorouracil—colon cancer	0.000223	0.00635	CcSEcCtD
Bumetanide—Hyperhidrosis—Vincristine—colon cancer	0.000222	0.00631	CcSEcCtD
Bumetanide—Thrombocytopenia—Irinotecan—colon cancer	0.000219	0.00622	CcSEcCtD
Bumetanide—PTGS2—vagina—colon cancer	0.000218	0.0043	CbGeAlD
Bumetanide—Hyperhidrosis—Irinotecan—colon cancer	0.000216	0.00615	CcSEcCtD
Bumetanide—Hypotension—Vincristine—colon cancer	0.000214	0.0061	CcSEcCtD
Bumetanide—CA12—Metabolism—CA7—colon cancer	0.000211	0.0028	CbGpPWpGaD
Bumetanide—Thrombocytopenia—Fluorouracil—colon cancer	0.000209	0.00596	CcSEcCtD
Bumetanide—Hypotension—Irinotecan—colon cancer	0.000209	0.00594	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000204	0.0058	CcSEcCtD
Bumetanide—Hypotension—Fluorouracil—colon cancer	0.0002	0.00569	CcSEcCtD
Bumetanide—Erythema multiforme—Capecitabine—colon cancer	0.000199	0.00566	CcSEcCtD
Bumetanide—Fatigue—Vincristine—colon cancer	0.000198	0.00563	CcSEcCtD
Bumetanide—Fatigue—Irinotecan—colon cancer	0.000192	0.00548	CcSEcCtD
Bumetanide—Pancreatitis—Methotrexate—colon cancer	0.000192	0.00546	CcSEcCtD
Bumetanide—Abdominal discomfort—Methotrexate—colon cancer	0.000187	0.00534	CcSEcCtD
Bumetanide—Gastrointestinal pain—Vincristine—colon cancer	0.000187	0.00534	CcSEcCtD
Bumetanide—PTGS2—liver—colon cancer	0.000184	0.00363	CbGeAlD
Bumetanide—Gastrointestinal pain—Irinotecan—colon cancer	0.000183	0.0052	CcSEcCtD
Bumetanide—Abdominal pain—Vincristine—colon cancer	0.000181	0.00516	CcSEcCtD
Bumetanide—Abdominal pain—Irinotecan—colon cancer	0.000176	0.00503	CcSEcCtD
Bumetanide—SLC10A1—Metabolism—CA7—colon cancer	0.000176	0.00234	CbGpPWpGaD
Bumetanide—Muscle spasms—Capecitabine—colon cancer	0.000176	0.00501	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000173	0.00492	CcSEcCtD
Bumetanide—Renal failure—Methotrexate—colon cancer	0.000171	0.00488	CcSEcCtD
Bumetanide—Urticaria—Fluorouracil—colon cancer	0.00017	0.00484	CcSEcCtD
Bumetanide—CA4—Metabolism—CA7—colon cancer	0.000168	0.00223	CbGpPWpGaD
Bumetanide—Sweating—Methotrexate—colon cancer	0.000167	0.00476	CcSEcCtD
Bumetanide—Vertigo—Capecitabine—colon cancer	0.000164	0.00468	CcSEcCtD
Bumetanide—Asthenia—Vincristine—colon cancer	0.000164	0.00468	CcSEcCtD
Bumetanide—Leukopenia—Capecitabine—colon cancer	0.000164	0.00467	CcSEcCtD
Bumetanide—Asthenia—Irinotecan—colon cancer	0.00016	0.00456	CcSEcCtD
Bumetanide—Diarrhoea—Vincristine—colon cancer	0.000157	0.00447	CcSEcCtD
Bumetanide—Arthralgia—Capecitabine—colon cancer	0.000156	0.00444	CcSEcCtD
Bumetanide—Chest pain—Capecitabine—colon cancer	0.000156	0.00444	CcSEcCtD
Bumetanide—Diarrhoea—Irinotecan—colon cancer	0.000153	0.00435	CcSEcCtD
Bumetanide—Dry mouth—Capecitabine—colon cancer	0.000152	0.00434	CcSEcCtD
Bumetanide—CA14—Metabolism—CHST5—colon cancer	0.000152	0.00201	CbGpPWpGaD
Bumetanide—CA14—Metabolism—ODC1—colon cancer	0.000152	0.00201	CbGpPWpGaD
Bumetanide—Dizziness—Vincristine—colon cancer	0.000152	0.00432	CcSEcCtD
Bumetanide—Pruritus—Fluorouracil—colon cancer	0.000151	0.00431	CcSEcCtD
Bumetanide—Erythema multiforme—Methotrexate—colon cancer	0.000148	0.00422	CcSEcCtD
Bumetanide—CA5A—Metabolism—CHST5—colon cancer	0.000148	0.00196	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—ODC1—colon cancer	0.000148	0.00196	CbGpPWpGaD
Bumetanide—Dizziness—Irinotecan—colon cancer	0.000148	0.0042	CcSEcCtD
Bumetanide—Diarrhoea—Fluorouracil—colon cancer	0.000146	0.00417	CcSEcCtD
Bumetanide—Thrombocytopenia—Capecitabine—colon cancer	0.000146	0.00417	CcSEcCtD
Bumetanide—Vomiting—Vincristine—colon cancer	0.000146	0.00415	CcSEcCtD
Bumetanide—SLC12A4—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000145	0.00193	CbGpPWpGaD
Bumetanide—CFTR—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000145	0.00193	CbGpPWpGaD
Bumetanide—SLC12A5—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000145	0.00193	CbGpPWpGaD
Bumetanide—Rash—Vincristine—colon cancer	0.000145	0.00412	CcSEcCtD
Bumetanide—Hyperhidrosis—Capecitabine—colon cancer	0.000144	0.00411	CcSEcCtD
Bumetanide—Dermatitis—Vincristine—colon cancer	0.000144	0.00411	CcSEcCtD
Bumetanide—Headache—Vincristine—colon cancer	0.000144	0.00409	CcSEcCtD
Bumetanide—Vomiting—Irinotecan—colon cancer	0.000142	0.00404	CcSEcCtD
Bumetanide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—colon cancer	0.000141	0.00188	CbGpPWpGaD
Bumetanide—Dizziness—Fluorouracil—colon cancer	0.000141	0.00403	CcSEcCtD
Bumetanide—PTGS2—lymph node—colon cancer	0.000141	0.00278	CbGeAlD
Bumetanide—Rash—Irinotecan—colon cancer	0.000141	0.00401	CcSEcCtD
Bumetanide—Dermatitis—Irinotecan—colon cancer	0.000141	0.004	CcSEcCtD
Bumetanide—Headache—Irinotecan—colon cancer	0.00014	0.00398	CcSEcCtD
Bumetanide—Hypotension—Capecitabine—colon cancer	0.00014	0.00398	CcSEcCtD
Bumetanide—CA5B—Metabolism—CHST5—colon cancer	0.000138	0.00183	CbGpPWpGaD
Bumetanide—CA7—Metabolism—ODC1—colon cancer	0.000138	0.00183	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—ODC1—colon cancer	0.000138	0.00183	CbGpPWpGaD
Bumetanide—CA7—Metabolism—CHST5—colon cancer	0.000138	0.00183	CbGpPWpGaD
Bumetanide—Nausea—Vincristine—colon cancer	0.000136	0.00388	CcSEcCtD
Bumetanide—CA9—Metabolism—CA7—colon cancer	0.000136	0.0018	CbGpPWpGaD
Bumetanide—Vomiting—Fluorouracil—colon cancer	0.000136	0.00387	CcSEcCtD
Bumetanide—Rash—Fluorouracil—colon cancer	0.000135	0.00384	CcSEcCtD
Bumetanide—Dermatitis—Fluorouracil—colon cancer	0.000135	0.00384	CcSEcCtD
Bumetanide—Headache—Fluorouracil—colon cancer	0.000134	0.00381	CcSEcCtD
Bumetanide—SLC22A7—Fluoropyrimidine Activity—TP53—colon cancer	0.000133	0.00176	CbGpPWpGaD
Bumetanide—Nausea—Irinotecan—colon cancer	0.000133	0.00378	CcSEcCtD
Bumetanide—Fatigue—Capecitabine—colon cancer	0.000129	0.00367	CcSEcCtD
Bumetanide—CA12—Metabolism—CHST5—colon cancer	0.000128	0.0017	CbGpPWpGaD
Bumetanide—CA12—Metabolism—ODC1—colon cancer	0.000128	0.0017	CbGpPWpGaD
Bumetanide—Nausea—Fluorouracil—colon cancer	0.000127	0.00362	CcSEcCtD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000126	0.00167	CbGpPWpGaD
Bumetanide—CA9—HIF-1-alpha transcription factor network—EP300—colon cancer	0.000125	0.00165	CbGpPWpGaD
Bumetanide—SLC12A2—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000123	0.00164	CbGpPWpGaD
Bumetanide—PTGS2—S1P1 pathway—VEGFA—colon cancer	0.000123	0.00164	CbGpPWpGaD
Bumetanide—Vertigo—Methotrexate—colon cancer	0.000122	0.00349	CcSEcCtD
Bumetanide—Gastrointestinal pain—Capecitabine—colon cancer	0.000122	0.00348	CcSEcCtD
Bumetanide—Leukopenia—Methotrexate—colon cancer	0.000122	0.00347	CcSEcCtD
Bumetanide—Urticaria—Capecitabine—colon cancer	0.000119	0.00338	CcSEcCtD
Bumetanide—Abdominal pain—Capecitabine—colon cancer	0.000118	0.00336	CcSEcCtD
Bumetanide—CA9—HIF-1-alpha transcription factor network—VEGFA—colon cancer	0.000118	0.00157	CbGpPWpGaD
Bumetanide—Chest pain—Methotrexate—colon cancer	0.000116	0.0033	CcSEcCtD
Bumetanide—Arthralgia—Methotrexate—colon cancer	0.000116	0.0033	CcSEcCtD
Bumetanide—Thrombocytopenia—Methotrexate—colon cancer	0.000109	0.0031	CcSEcCtD
Bumetanide—Hyperhidrosis—Methotrexate—colon cancer	0.000108	0.00306	CcSEcCtD
Bumetanide—Asthenia—Capecitabine—colon cancer	0.000107	0.00305	CcSEcCtD
Bumetanide—SLC10A1—Metabolism—CHST5—colon cancer	0.000107	0.00142	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—ODC1—colon cancer	0.000107	0.00142	CbGpPWpGaD
Bumetanide—Pruritus—Capecitabine—colon cancer	0.000106	0.00301	CcSEcCtD
Bumetanide—Hypotension—Methotrexate—colon cancer	0.000104	0.00296	CcSEcCtD
Bumetanide—Diarrhoea—Capecitabine—colon cancer	0.000102	0.00291	CcSEcCtD
Bumetanide—CA4—Metabolism—ODC1—colon cancer	0.000102	0.00135	CbGpPWpGaD
Bumetanide—CA4—Metabolism—CHST5—colon cancer	0.000102	0.00135	CbGpPWpGaD
Bumetanide—Dizziness—Capecitabine—colon cancer	9.88e-05	0.00281	CcSEcCtD
Bumetanide—Fatigue—Methotrexate—colon cancer	9.59e-05	0.00273	CcSEcCtD
Bumetanide—Vomiting—Capecitabine—colon cancer	9.5e-05	0.00271	CcSEcCtD
Bumetanide—Rash—Capecitabine—colon cancer	9.42e-05	0.00268	CcSEcCtD
Bumetanide—Dermatitis—Capecitabine—colon cancer	9.41e-05	0.00268	CcSEcCtD
Bumetanide—Headache—Capecitabine—colon cancer	9.36e-05	0.00267	CcSEcCtD
Bumetanide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—colon cancer	9.17e-05	0.00122	CbGpPWpGaD
Bumetanide—Gastrointestinal pain—Methotrexate—colon cancer	9.09e-05	0.00259	CcSEcCtD
Bumetanide—Nausea—Capecitabine—colon cancer	8.87e-05	0.00253	CcSEcCtD
Bumetanide—Urticaria—Methotrexate—colon cancer	8.84e-05	0.00252	CcSEcCtD
Bumetanide—Abdominal pain—Methotrexate—colon cancer	8.79e-05	0.0025	CcSEcCtD
Bumetanide—SLCO1A2—Metabolism—CA7—colon cancer	8.68e-05	0.00115	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	8.59e-05	0.00114	CbGpPWpGaD
Bumetanide—CA9—Metabolism—ODC1—colon cancer	8.24e-05	0.00109	CbGpPWpGaD
Bumetanide—CA9—Metabolism—CHST5—colon cancer	8.24e-05	0.00109	CbGpPWpGaD
Bumetanide—Asthenia—Methotrexate—colon cancer	7.98e-05	0.00227	CcSEcCtD
Bumetanide—Pruritus—Methotrexate—colon cancer	7.87e-05	0.00224	CcSEcCtD
Bumetanide—Diarrhoea—Methotrexate—colon cancer	7.61e-05	0.00217	CcSEcCtD
Bumetanide—CA9—HIF-1-alpha transcription factor network—AKT1—colon cancer	7.53e-05	0.001	CbGpPWpGaD
Bumetanide—Dizziness—Methotrexate—colon cancer	7.35e-05	0.00209	CcSEcCtD
Bumetanide—SLC12A1—Transmembrane transport of small molecules—ABCB1—colon cancer	7.34e-05	0.000974	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	7.23e-05	0.000959	CbGpPWpGaD
Bumetanide—Vomiting—Methotrexate—colon cancer	7.07e-05	0.00201	CcSEcCtD
Bumetanide—Rash—Methotrexate—colon cancer	7.01e-05	0.002	CcSEcCtD
Bumetanide—Dermatitis—Methotrexate—colon cancer	7.01e-05	0.002	CcSEcCtD
Bumetanide—Headache—Methotrexate—colon cancer	6.97e-05	0.00198	CcSEcCtD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	6.74e-05	0.000895	CbGpPWpGaD
Bumetanide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—colon cancer	6.7e-05	0.000889	CbGpPWpGaD
Bumetanide—Nausea—Methotrexate—colon cancer	6.61e-05	0.00188	CcSEcCtD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—EP300—colon cancer	6.41e-05	0.000851	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—SRC—colon cancer	6.24e-05	0.000828	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	6.08e-05	0.000806	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	6e-05	0.000796	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	5.78e-05	0.000767	CbGpPWpGaD
Bumetanide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—colon cancer	5.71e-05	0.000758	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—MYC—colon cancer	5.59e-05	0.000742	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	5.47e-05	0.000726	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—ODC1—colon cancer	5.26e-05	0.000698	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—CHST5—colon cancer	5.26e-05	0.000698	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—CA7—colon cancer	5.24e-05	0.000696	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	5.16e-05	0.000685	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	4.51e-05	0.000599	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	4.43e-05	0.000588	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.41e-05	0.000585	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	4.39e-05	0.000583	CbGpPWpGaD
Bumetanide—SLC22A11—Transmembrane transport of small molecules—ABCB1—colon cancer	4.38e-05	0.000581	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—CDKN1A—colon cancer	4.32e-05	0.000574	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—CCND1—colon cancer	4.3e-05	0.000571	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	4.27e-05	0.000566	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—CDKN1A—colon cancer	4.16e-05	0.000553	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—EP300—colon cancer	4.11e-05	0.000546	CbGpPWpGaD
Bumetanide—CA14—Metabolism—ABCB1—colon cancer	4.01e-05	0.000532	CbGpPWpGaD
Bumetanide—SLC22A7—Transmembrane transport of small molecules—ABCB1—colon cancer	3.97e-05	0.000528	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—EP300—colon cancer	3.96e-05	0.000526	CbGpPWpGaD
Bumetanide—CA14—Metabolism—TYMS—colon cancer	3.94e-05	0.000522	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—ABCB1—colon cancer	3.91e-05	0.000518	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—VEGFA—colon cancer	3.9e-05	0.000517	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—TYMS—colon cancer	3.84e-05	0.000509	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CHST5—colon cancer	3.79e-05	0.000503	CbGpPWpGaD
Bumetanide—PTGS2—Disease—LGR5—colon cancer	3.79e-05	0.000503	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—NRAS—colon cancer	3.71e-05	0.000492	CbGpPWpGaD
Bumetanide—CA7—Metabolism—ABCB1—colon cancer	3.65e-05	0.000484	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—ABCB1—colon cancer	3.65e-05	0.000484	CbGpPWpGaD
Bumetanide—CA7—Metabolism—TYMS—colon cancer	3.58e-05	0.000475	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—TYMS—colon cancer	3.58e-05	0.000475	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.47e-05	0.000461	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—MYC—colon cancer	3.45e-05	0.000458	CbGpPWpGaD
Bumetanide—CA12—Metabolism—ABCB1—colon cancer	3.38e-05	0.000448	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CASP3—colon cancer	3.37e-05	0.000447	CbGpPWpGaD
Bumetanide—SLC22A8—Transmembrane transport of small molecules—ABCB1—colon cancer	3.34e-05	0.000443	CbGpPWpGaD
Bumetanide—CA12—Metabolism—TYMS—colon cancer	3.32e-05	0.00044	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CCND1—colon cancer	3.28e-05	0.000435	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—colon cancer	3.25e-05	0.000432	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—KRAS—colon cancer	3.19e-05	0.000423	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—CHST5—colon cancer	3.18e-05	0.000421	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—ODC1—colon cancer	3.18e-05	0.000421	CbGpPWpGaD
Bumetanide—SLCO1A2—Transmembrane transport of small molecules—ABCB1—colon cancer	2.97e-05	0.000394	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—TP53—colon cancer	2.94e-05	0.000391	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.89e-05	0.000383	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—ABCB1—colon cancer	2.82e-05	0.000375	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PPARG—colon cancer	2.79e-05	0.00037	CbGpPWpGaD
Bumetanide—SLC22A6—Transmembrane transport of small molecules—ABCB1—colon cancer	2.79e-05	0.00037	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—TYMS—colon cancer	2.77e-05	0.000368	CbGpPWpGaD
Bumetanide—PTGS2—Disease—AXIN2—colon cancer	2.72e-05	0.000361	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PPARG—colon cancer	2.72e-05	0.000361	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—HRAS—colon cancer	2.71e-05	0.00036	CbGpPWpGaD
Bumetanide—CA4—Metabolism—ABCB1—colon cancer	2.69e-05	0.000358	CbGpPWpGaD
Bumetanide—CA4—Metabolism—TYMS—colon cancer	2.65e-05	0.000351	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—MYC—colon cancer	2.63e-05	0.000349	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—TGFB1—colon cancer	2.62e-05	0.000348	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—EGFR—colon cancer	2.57e-05	0.000341	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PPARG—colon cancer	2.54e-05	0.000337	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PPARG—colon cancer	2.54e-05	0.000337	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PPARG—colon cancer	2.35e-05	0.000312	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.29e-05	0.000304	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.23e-05	0.000296	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.21e-05	0.000293	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PTGS2—colon cancer	2.19e-05	0.000291	CbGpPWpGaD
Bumetanide—CA9—Metabolism—ABCB1—colon cancer	2.18e-05	0.000289	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.17e-05	0.000288	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—TP53—colon cancer	2.16e-05	0.000287	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.16e-05	0.000286	CbGpPWpGaD
Bumetanide—CA9—Metabolism—TYMS—colon cancer	2.14e-05	0.000284	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PTGS2—colon cancer	2.14e-05	0.000284	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.14e-05	0.000283	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	2.05e-05	0.000273	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	2e-05	0.000265	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PTGS2—colon cancer	2e-05	0.000265	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PTGS2—colon cancer	2e-05	0.000265	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PPARG—colon cancer	1.96e-05	0.000261	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.95e-05	0.000258	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PPARG—colon cancer	1.87e-05	0.000249	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PTGS2—colon cancer	1.85e-05	0.000245	CbGpPWpGaD
Bumetanide—CA14—Metabolism—EP300—colon cancer	1.82e-05	0.000242	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.79e-05	0.000238	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.79e-05	0.000237	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—EP300—colon cancer	1.78e-05	0.000236	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.75e-05	0.000232	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.71e-05	0.000227	CbGpPWpGaD
Bumetanide—CA7—Metabolism—EP300—colon cancer	1.66e-05	0.00022	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—EP300—colon cancer	1.66e-05	0.00022	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.65e-05	0.000219	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PTGS2—colon cancer	1.55e-05	0.000205	CbGpPWpGaD
Bumetanide—CA12—Metabolism—EP300—colon cancer	1.54e-05	0.000204	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.52e-05	0.000202	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PPARG—colon cancer	1.51e-05	0.000201	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PTGS2—colon cancer	1.47e-05	0.000196	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.47e-05	0.000195	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.42e-05	0.000188	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—ABCB1—colon cancer	1.39e-05	0.000184	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—TYMS—colon cancer	1.36e-05	0.000181	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PIK3CA—colon cancer	1.35e-05	0.000179	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PIK3CA—colon cancer	1.32e-05	0.000175	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.31e-05	0.000174	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—EP300—colon cancer	1.29e-05	0.000171	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.24e-05	0.000165	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PIK3CA—colon cancer	1.23e-05	0.000163	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PIK3CA—colon cancer	1.23e-05	0.000163	CbGpPWpGaD
Bumetanide—CA4—Metabolism—EP300—colon cancer	1.23e-05	0.000163	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PTGS2—colon cancer	1.19e-05	0.000158	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PIK3CA—colon cancer	1.14e-05	0.000151	CbGpPWpGaD
Bumetanide—CA14—Metabolism—AKT1—colon cancer	1.1e-05	0.000146	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—AKT1—colon cancer	1.07e-05	0.000143	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.05e-05	0.000139	CbGpPWpGaD
Bumetanide—CA7—Metabolism—AKT1—colon cancer	1e-05	0.000133	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—AKT1—colon cancer	1e-05	0.000133	CbGpPWpGaD
Bumetanide—CA9—Metabolism—EP300—colon cancer	9.91e-06	0.000131	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PPARG—colon cancer	9.67e-06	0.000128	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PIK3CA—colon cancer	9.51e-06	0.000126	CbGpPWpGaD
Bumetanide—CA12—Metabolism—AKT1—colon cancer	9.29e-06	0.000123	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PIK3CA—colon cancer	9.07e-06	0.00012	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	8.58e-06	0.000114	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—ABCB1—colon cancer	8.39e-06	0.000111	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—TYMS—colon cancer	8.24e-06	0.000109	CbGpPWpGaD
Bumetanide—PTGS2—Disease—FGFR3—colon cancer	7.87e-06	0.000104	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—AKT1—colon cancer	7.77e-06	0.000103	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PTGS2—colon cancer	7.6e-06	0.000101	CbGpPWpGaD
Bumetanide—CA4—Metabolism—AKT1—colon cancer	7.41e-06	9.83e-05	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PIK3CA—colon cancer	7.33e-06	9.73e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—APC—colon cancer	7.22e-06	9.58e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—BRAF—colon cancer	6.79e-06	9.01e-05	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.34e-06	8.42e-05	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—EP300—colon cancer	6.32e-06	8.39e-05	CbGpPWpGaD
Bumetanide—CA9—Metabolism—AKT1—colon cancer	5.99e-06	7.95e-05	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PPARG—colon cancer	5.84e-06	7.75e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CTNNB1—colon cancer	4.91e-06	6.51e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CDKN1A—colon cancer	4.79e-06	6.36e-05	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PIK3CA—colon cancer	4.68e-06	6.21e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—EP300—colon cancer	4.56e-06	6.05e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—SRC—colon cancer	4.43e-06	5.89e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—NRAS—colon cancer	4.27e-06	5.66e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—MYC—colon cancer	3.97e-06	5.27e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—TGFB1—colon cancer	3.96e-06	5.26e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—EGFR—colon cancer	3.89e-06	5.16e-05	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—AKT1—colon cancer	3.82e-06	5.07e-05	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—EP300—colon cancer	3.82e-06	5.07e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—KRAS—colon cancer	3.67e-06	4.87e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PIK3CA—colon cancer	3.37e-06	4.48e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—HRAS—colon cancer	3.12e-06	4.14e-05	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PIK3CA—colon cancer	2.83e-06	3.75e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—AKT1—colon cancer	2.76e-06	3.66e-05	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—AKT1—colon cancer	2.31e-06	3.06e-05	CbGpPWpGaD
